Sarepta Therapeutics, Inc. SRPT Business Segments — Gain Loss On Investments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnInvestments.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — gain loss on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s business segments — gain loss on investments?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — gain loss on investments of $1.71M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — gain loss on investments changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — gain loss on investments decreased by 98.1% year-over-year, from $90.73M to $1.71M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — gain loss on investments?
- Over 2 years (2023 to 2025), Sarepta Therapeutics, Inc.'s business segments — gain loss on investments has grown at a 222.8% compound annual growth rate (CAGR), from $1.53M to -$15.91M.
- What does business segments — gain loss on investments mean?
- Represents the net realized and unrealized gains or losses recognized on the segment's investment portfolio. This metric reflects the performance of non-operating financial assets and market-driven valuation changes. It provides insight into the segment's secondary financial returns beyond core business operations.